GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aarti Pharmalabs Ltd (BOM:543748) » Definitions » Price-to-Owner-Earnings

Aarti Pharmalabs (BOM:543748) Price-to-Owner-Earnings : 90.58 (As of Jun. 01, 2025)


View and export this data going back to 2023. Start your Free Trial

What is Aarti Pharmalabs Price-to-Owner-Earnings?

As of today (2025-06-01), Aarti Pharmalabs's share price is ₹910.35. Aarti Pharmalabs's Owner Earnings per Share (TTM) ended in Mar. 2025 was ₹10.05. It's Price-to-Owner-Earnings for today is 90.58.


The historical rank and industry rank for Aarti Pharmalabs's Price-to-Owner-Earnings or its related term are showing as below:

BOM:543748' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 67.55   Med: 73.06   Max: 86.19
Current: 86.19

During the past 5 years, the highest Price-to-Owner-Earnings of Aarti Pharmalabs was 86.19. The lowest was 67.55. And the median was 73.06.


BOM:543748's Price-to-Owner-Earnings is ranked worse than
88.59% of 447 companies
in the Drug Manufacturers industry
Industry Median: 25.25 vs BOM:543748: 86.19

As of today (2025-06-01), Aarti Pharmalabs's share price is ₹910.35. Aarti Pharmalabs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was ₹30.04. Therefore, Aarti Pharmalabs's PE Ratio (TTM) for today is 30.30.

As of today (2025-06-01), Aarti Pharmalabs's share price is ₹910.35. Aarti Pharmalabs's EPS without NRI for the trailing twelve months (TTM) ended in was ₹30.04. Therefore, Aarti Pharmalabs's PE Ratio without NRI for today is 30.30.

During the past 5 years, Aarti Pharmalabs's highest PE Ratio without NRI was 29.30. The lowest was 12.86. And the median was 22.76.


Aarti Pharmalabs Price-to-Owner-Earnings Historical Data

The historical data trend for Aarti Pharmalabs's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aarti Pharmalabs Price-to-Owner-Earnings Chart

Aarti Pharmalabs Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
Price-to-Owner-Earnings
- - - - 74.48

Aarti Pharmalabs Quarterly Data
Mar21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 74.48

Competitive Comparison of Aarti Pharmalabs's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Aarti Pharmalabs's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aarti Pharmalabs's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aarti Pharmalabs's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Aarti Pharmalabs's Price-to-Owner-Earnings falls into.


;
;

Aarti Pharmalabs Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Aarti Pharmalabs's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=910.35/10.05
=90.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aarti Pharmalabs  (BOM:543748) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Aarti Pharmalabs Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Aarti Pharmalabs's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Aarti Pharmalabs Business Description

Traded in Other Exchanges
Address
Mulund Goregaon Link Road, 2nd floor, 204, Udyog Kshetra, Mulund West, Mumbai, MH, IND, 400080
Aarti Pharmalabs Ltd manufactures pharmaceuticals and nutraceuticals with a footprint. It manufactures Active Pharmaceutical Ingredients (API), pharmaceutical intermediates, and xanthine derivatives in India. It also offers Contract Development and Manufacturing Services (CDMS) for drug substance (NCE, RSM, Intermediates) projects. Geographically, the company generates maximum revenue from its customers located outside India.

Aarti Pharmalabs Headlines

No Headlines